Company: GHRS
Filing Date: 2025-02-27
Form Type: 20-F
Source: 0001140361-25-006175
Chunk: 85

Company: GH Research PLC
Filing Date: 2025-02-27
Form: 20-F
Item: Item 5
Chunk 85
---
----------

•   comply with ongoing regulatory requirements for products approved for commercial sale, if ever;
---------------------------------------------------------------------------------------------------
  Table of Contents

•   acquire or in-license other product candidates, medical devices to deliver our product candidates, and other technologies; and
----------------------------------------------------------------------------------------------------------------------------------

•   incur increased costs as a result of operating as a public company.
-----------------------------------------------------------------------
 
As of December 31, 2024, we had cash, cash equivalents, other financial assets and marketable securities of $182.6 million, compared to cash, cash equivalents, other financial assts and marketable securities of $222.7 million as of December 31, 2023. We believe that our existing cash, cash equivalents, other financial assets and marketable securities will be sufficient for us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. However, we have based this estimate on assumptions that may prove to be wrong and we could exhaust our capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with product development, we may incorrectly estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates. Our present and future funding requirements and timing and amount of our operating expenditures, both in the near- and long-term, depend on many factors, including, but not limited to:
 

•   the scope, progress, results and costs of researching and developing our GH001 and GH002 product candidates, additional mebufotenin delivery approaches and the medical devices required to deliver these therapies for our initial
                                                                            and any additional indications, as well as other product candidates we may develop;                                                                        
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

•   the timing and uncertainty of, and the costs involved in, obtaining marketing approvals for our GH001 and GH002 product candidates including the medical devices required to deliver these therapies for our initial and any
                                                                          additional indications, and other product candidates we may develop and pursue;                                                                       
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

•   the duration of the clinical hold on the study we proposed in our IND for GH001, including the progression of, and associated costs from, any nonclinical programs and any other work necessary to lift the clinical hold, as well as
                                                                                discussions with the FDA and the outcomes and resolution of such discussions;                                                                            
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

•   the number of future product candidates that we may pursue and their development requirements;
--------------------------------------------------------------------------------------------------

•   the number of jurisdictions in which we plan to seek regulatory approvals;
------------------------------------------------------------------------------

•   if approved,